Researchers at the Icahn School of Medicine at Mount Sinai in New York, Boston Medical Center, and Boston University ...
Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback